Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

2021539 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 10, pp. 1403-1415

Field-Weighted Citation Impact: 33.02